Reuters: Health News 3 April 2018

Pfizer signs deal with Allogene to develop cancer cell therapy

(Reuters) - Pfizer Inc said on Tuesday it signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake, to further develop its allogenic CAR T cell therapy.

Read More →

High-flying biotech Loxo tempers bullish view for cancer drug

STAMFORD, Connecticut (Reuters) - In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany's Bayer . Its stock tripled in the past year.

Read More →